Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Management of protease inhibitor-associated diarrhea.

Sherman DS, Fish DN.

Clin Infect Dis. 2000 Jun;30(6):908-14. Epub 2000 Jun 14. Review.

PMID:
10854364
2.
3.

Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.

Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.

Pediatrics. 2005 Feb;115(2):e173-82. Epub 2005 Jan 3.

PMID:
15629958
4.

HIV-1 protease inhibitors.

Eron JJ Jr.

Clin Infect Dis. 2000 Jun;30 Suppl 2:S160-70. Review.

PMID:
10860901
5.

Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.

Guest JL, Ruffin C, Tschampa JM, DeSilva KE, Rimland D.

Pharmacotherapy. 2004 Jun;24(6):727-35.

PMID:
15222662
6.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
7.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
8.

Oat bran treats diarrhea.

Vazquez E.

Posit Aware. 1999 Mar-Apr;10(2):16.

PMID:
11366840
9.

A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.

Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.

West Afr J Med. 2002 Apr-Jun;21(2):83-6.

PMID:
12403023
10.

The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients.

Jensen-Fangel S, Justesen US, Black FT, Pedersen C, Obel N.

HIV Med. 2003 Jan;4(1):48-52.

11.

Management of protease inhibitor-associated hyperlipidemia.

Penzak SR, Chuck SK.

Am J Cardiovasc Drugs. 2002;2(2):91-106. Review.

PMID:
14727985
12.

Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children.

Buchacz K, Cervia JS, Lindsey JC, Hughes MD, Seage GR 3rd, Dankner WM, Oleske JM, Moye J.

Pediatrics. 2001 Oct;108(4):E72.

PMID:
11581480
13.

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

Calza L, Manfredi R, Chiodo F.

J Antimicrob Chemother. 2004 Jan;53(1):10-4. Epub 2003 Nov 25. Review.

PMID:
14645323
14.

Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.

Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G.

Dig Liver Dis. 2006 Jun;38(6):363-73. Epub 2006 May 2. Review.

PMID:
16631422
15.

Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.

Rhew DC, Bernal M, Aguilar D, Iloeje U, Goetz MB.

Clin Infect Dis. 2003 Oct 1;37(7):959-72. Epub 2003 Sep 12. Review.

PMID:
13130409
16.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
17.
18.

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.

Tsiodras S, Mantzoros C, Hammer S, Samore M.

Arch Intern Med. 2000 Jul 10;160(13):2050-6.

PMID:
10888979
19.

The role of loperamide in gastrointestinal disorders.

Hanauer SB.

Rev Gastroenterol Disord. 2008 Winter;8(1):15-20. Review.

PMID:
18477966
20.

The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children.

Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL.

Pediatrics. 2001 May;107(5):E77.

PMID:
11331727

Supplemental Content

Support Center